Press & News

People are different and so is their cancer, patients should be treated individually.

Invitation to 2cureX Strategy Deep-Dive

November 1, 2022

IR

Market developments and strategic progress in functional drug sensitivity testing

The market for functional drug sensitivity testing is gaining in importance and recognition. Having launched three CE-marked IVD tests for colorectal cancer and developed a distributor network covering 17 countries in Europe and the Middle East, 2cureX is perfectly poised to take advantage of the situation, despite the tough multi-faceted crisis we are living nowadays.

On Tuesday 15 November at 1 PM, 2cureX will be organising a Strategy Deep-Dive to discuss the company’s current position and its ongoing strategy. With promising results from a recent market survey, and the deep understanding of the (path to) market we have gained over the last 12 months, our management team and other experts are excited to provide an update of where we stand and where we are heading.

Topics will include:

  • A clear description of 2cureX's ongoing strategy
  • The market opportunity in colorectal cancer
  • Feedback from the market
  • Status of the execution of our strategy
  • Future goals.

To join the Strategy Deep-Dive, simply click here. In addition to the update, we look forward to answering any questions you may have in Q&A session with Fernando Andreu, our CEO, and Ole Thastrup, our founder and CSO.

Should you have any questions beforehand, or if you have a specific question you would like answered on the day, do not hesitate to contact Fernando under fa@2curex.com

Note for editors and the press:

For more information, please do not hesitate to get in touch. Send an email to:

Mark C. Gray
Director of Communications
mg@2curex.com